ARTICLE | Clinical News
EC approves rare disease drug from Chiesi
April 6, 2018 2:49 PM UTC
Chiesi Farmaceutici S.p.A. (Parma, Italy) said the European Commission approved an MAA for Lamzede velmanase alfa to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis, a rare lysosomal storage disease...
BCIQ Company Profiles